We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Outperforms Broader Market: What You Need to Know
Read MoreHide Full Article
Organon (OGN - Free Report) ended the recent trading session at $20.47, demonstrating a +0.89% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.54%. On the other hand, the Dow registered a gain of 0.72%, and the technology-centric Nasdaq increased by 0.65%.
Shares of the pharmaceutical company witnessed a gain of 0.35% over the previous month, trailing the performance of the Medical sector with its gain of 4.37% and the S&P 500's gain of 4.86%.
The upcoming earnings release of Organon will be of great interest to investors. The company is forecasted to report an EPS of $0.97, showcasing a 11.49% upward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $1.56 billion, reflecting a 2.44% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.33 per share and a revenue of $6.34 billion, signifying shifts of +4.59% and +1.28%, respectively, from the last year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Organon. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Organon is currently sporting a Zacks Rank of #4 (Sell).
From a valuation perspective, Organon is currently exchanging hands at a Forward P/E ratio of 4.68. This denotes a discount relative to the industry's average Forward P/E of 22.16.
Also, we should mention that OGN has a PEG ratio of 0.85. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical Services stocks are, on average, holding a PEG ratio of 1.57 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 173, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Organon (OGN) Outperforms Broader Market: What You Need to Know
Organon (OGN - Free Report) ended the recent trading session at $20.47, demonstrating a +0.89% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.54%. On the other hand, the Dow registered a gain of 0.72%, and the technology-centric Nasdaq increased by 0.65%.
Shares of the pharmaceutical company witnessed a gain of 0.35% over the previous month, trailing the performance of the Medical sector with its gain of 4.37% and the S&P 500's gain of 4.86%.
The upcoming earnings release of Organon will be of great interest to investors. The company is forecasted to report an EPS of $0.97, showcasing a 11.49% upward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $1.56 billion, reflecting a 2.44% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $4.33 per share and a revenue of $6.34 billion, signifying shifts of +4.59% and +1.28%, respectively, from the last year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Organon. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Organon is currently sporting a Zacks Rank of #4 (Sell).
From a valuation perspective, Organon is currently exchanging hands at a Forward P/E ratio of 4.68. This denotes a discount relative to the industry's average Forward P/E of 22.16.
Also, we should mention that OGN has a PEG ratio of 0.85. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical Services stocks are, on average, holding a PEG ratio of 1.57 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 173, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.